الفهرس 
Risk FactorsOnly 14 pages are availabe for public view
 |  | from | 212 |  |  |
| | | from | 212 | | |
Abstract
This retrospective study was performed to analyze the prog-nostic factors affecting survival of patients diagnosed with advanced non-small cell lung cancer (NSCLC) in Clinical Oncology department, Ain Shams University Hospitals & the International Medical Center between 2009 and 2017.
We identified 69 patients with advanced NSCLC. The mean age was 57.67 years. There were 43 males (62.3%) and 26 females (37.7%). The Eastern Cooperative Oncology group performance status (PS) 0 was identified in 17 patients (24.6%) and PS 1 and 2 were identified in 24 (42%) and 23 (33.3%) patients respectively. Forty patients (58%) were smokers. The majority of the patients had adeenocarcinoma (60.9%) as a histological subtype and 17 patients (24.6%) had squamous ell carcinoma.
The stage of the disease according to the American joint Committee on Cancer (AJCC) was as follow: stage IIIA 9 (13%), stage IIIB 22 (31.9%) and stage IV 38 (55.1%). The initial treatment modality (first-line therapy) was chemother-apy in 40 patients (57.71%) and concurrent chemoradiation
(CRT) in 20 patients (28.97%). Nine patients (13%) received no treatment (best supportive care).In univariate analysis; female patients (p=0.04), PS 0 (p=0.001), never smoking (p=0.001), stage IIIA (p=0.008) and concurrent CRT (p=0.001) had better overall survival (OS).
In multivariate analysis, PS (p=.001), stage (p=.001) and type of initial treatment (p=.019) were determined as the inde-pendent prognostic factors affecting survival.